Trial Profile
Efficacy and toxicity of lutetium-177-DOTATATE in patients with progressive metastatic neuroendocrine tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2018
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 06 Feb 2018 New trial record